# Senolytics after cancer treatment

Source: https://onco.cc/technologies/rejuv-frontier-senolytics/  
OnCo record `rejuv-frontier-senolytics` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Senolytics are drugs meant to kill the worn-out cells that chemotherapy leaves behind. The idea is good and the animal work is striking. The human evidence is four small trials in other diseases, none in cancer survivors, and the one properly randomised trial missed its main target. Nobody should be buying these.

## Summary

The best studied combination is dasatinib, a leukaemia drug, with quercetin, a plant flavonol, given intermittently rather than continuously. The first human study was open-label, in 14 people with idiopathic pulmonary fibrosis: walking distance, gait speed and chair-stand time improved significantly, there was no control group, and pulmonary function and the frailty index did not change. A second open-label study in nine people with diabetic kidney disease showed that three days of the combination reduced p16INK4a and p21CIP1 positive cells in fat and skin eleven days later, the first direct demonstration that a senolytic clears senescent cells in a person.

The only randomised trial of any size is in postmenopausal women, not survivors: 60 participants given intermittent dasatinib plus quercetin for 20 weeks. The primary endpoint, change in the bone resorption marker CTx, did not differ between groups (median -4.1 per cent against -7.7 per cent, P = 0.611). Bone formation (P1NP) rose by 16 per cent against control at two and four weeks but not at 20. In an exploratory subgroup with the highest T-cell p16 levels, CTx fell and radius bone density rose. No serious adverse events occurred. The authors call the subgroup a hypothesis for further study, and that is what it is.

Fisetin, another flavonol, is in trials but has no completed randomised result in cancer survivors. Navitoclax is a genuine senolytic in the laboratory but inhibits BCL-xL, which is what platelets depend on, so dose-limiting thrombocytopenia has constrained it in oncology since its first trials; that toxicity is the reason the field moved to BCL-xL-degrading PROTACs and to dasatinib-based regimens. Dasatinib is a prescription cancer drug with its own toxicity, including pleural effusion and bleeding, and it interacts with CYP3A4 inhibitors. Quercetin at trial doses is far above any dietary amount. OnCo holds this as a research idea, not an option; the idea record is linked below.

## Fields

- Kind: Technology
- Status: phase-2
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; evidence:insufficient; senescence
- Principle: Senescent cells survive by upregulating anti-apoptotic networks (BCL-2 family, PI3K/AKT, p53/p21/serpins). Senolytics transiently disable those networks so that senescent cells, which sit in a pro-apoptotic internal environment, die while normal cells do not. Intermittent dosing follows from the mechanism: the cells do not come back immediately, so continuous exposure is not needed.
- Strengths: Direct evidence in people that the drugs clear senescent cells from tissue; Intermittent dosing limits cumulative exposure; A clear, measurable mechanism tied to a documented effect of chemotherapy
- Limitations: No completed randomised trial in cancer survivors; The one randomised trial of adequate design missed its primary endpoint; Dasatinib is a prescription cancer drug with real toxicity and interactions; Navitoclax causes dose-limiting thrombocytopenia; Clearing senescent cells could in principle remove a barrier to tumour regrowth, which no human trial has yet addressed

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Senolytic
- Farr et al., Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (Nat Med 2024): https://doi.org/10.1038/s41591-024-03096-2
- Justice et al., Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study (EBioMedicine 2019): https://doi.org/10.1016/j.ebiom.2018.12.052
- Hickson et al., Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease (EBioMedicine 2019): https://doi.org/10.1016/j.ebiom.2019.08.069
- Smitherman et al., Accelerated aging among childhood, adolescent and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty (Cancer 2020): https://doi.org/10.1002/cncr.33112

## Connected records

- ideas: [Clear the zombie cells left behind by chemotherapy and radiotherapy](https://onco.cc/ideas/idea-bio1-senolytics-after-therapy/), [One-two punch: clear senescent cells after chemotherapy](https://onco.cc/ideas/idea-senolytics-after-chemo/)
- technologies: [Senescent cells and p16 after chemotherapy](https://onco.cc/technologies/rejuv-age-senescent-cells-after-treatment/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [What actually works after treatment](https://onco.cc/technologies/rejuv-frontier-what-works/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- drugs: [Dasatinib](https://onco.cc/drugs/dasatinib/), [Navitoclax](https://onco.cc/drugs/navitoclax/)
- pathways: [Cellular senescence](https://onco.cc/pathways/senescence/)
- terms: [Hallmark (2022): senescent cells](https://onco.cc/terms/senescent-cells/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/)
- bottlenecks: [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-frontier-senolytics.json